Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response (NCT03096418)
🩺 Plain-English Summary (8th-Grade Level)
The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.
Who can join: Review the eligibility criteria below.
Location: University of Iowa Health Care/Holden Comprehensive Cancer Center — Iowa City, Iowa
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- University of Iowa Health Care/Holden Comprehensive Cancer Center — Iowa City, Iowa
- University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (800) 622-8922
Email: clinicaltrials@cancer.wisc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasm Female
- Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients — New York, New York
- RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy — St Louis, Missouri
- A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2) — Darlinghurst, New South Wales
- The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI — Washington D.C., District of Columbia
Explore by condition: All Breast Neoplasm Female clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.